Spectrum Pharmaceuticals Announces Strategic Expansion and Realignment of Sales Force Post-Allos Therapeutics Acquisition in

  Spectrum Pharmaceuticals Announces Strategic Expansion and Realignment of
  Sales Force Post-Allos Therapeutics Acquisition in Order to Enhance Presence
  in U.S. Market

  *Sales force size expanded to over 60 professionals to support three
    marketed drugs, with the capacity to expand as additional drugs are added
    to the commercial pipeline
  *Six Regional Managers will lead business in the U.S. for FUSILEV®
    (levoleucovorin) for Injection, FOLOTYN® (pralatrexate injection), and
    ZEVALIN® (ibritumomab tiuxetan) Injection
  *Streamlining existing structure will lead to cost savings and efficiencies

Business Wire

HENDERSON, Nev. -- November 01, 2012

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully
integrated commercial and drug development operations with a primary focus in
hematology and oncology, today announced that the Company is undertaking a
strategic strengthening of its sales force in the U.S. The Company will
implement a structure of six geographic regions, with each regional manager
empowered to align sales resources and tailor promotional and other physician
and patient support initiatives to meet our customers’ needs. The realignment
of existing resources will result in a significantly greater hematology and
oncology footprint, an increased promotional reach, and more efficient
physician engagement.

Ken Keller, Executive Vice President, Chief Operating Officer of Spectrum
Pharmaceuticals, Inc., commented, “As Spectrum’s oncology portfolio expands,
it is essential we continue to build and grow our infrastructure and
capabilities. With the recent addition of FOLOTYN through the acquisition of
Allos, we have the opportunity to increase our investment in both the sales
force and promotional support to effectively manage our product portfolio.”

Mr. Keller continued, "The new structure will allow our sale force to
effectively promote all three products, resulting in a significant increase in
share of voice. Synergies will also result because ZEVALIN and FOLOTYN are
marketed to the same physicians. The realignment of commercial resources will
result in a largely customer-facing commercial organization, keeping with
Spectrum’s lean, cost-efficient business model. Additionally, we believe this
structure will allow us to effectively and efficiently add more oncology
products in the future."

About Spectrum Pharmaceuticals, Inc.

Spectrum Pharmaceuticals is a leading biotechnology company focused on
acquiring, developing, and commercializing drug products, with a primary focus
in oncology and hematology. Spectrum and its affiliates market three oncology
drugs ─ FUSILEV^® (levoleucovorin) for Injection in the U.S.; FOLOTYN^®
(pralatrexate injection), also marketed in the U.S.; and ZEVALIN^®
(ibritumomab tiuxetan) Injection for intravenous use, for which the Company
has worldwide marketing rights. Spectrum's strong track record in in-licensing
and acquiring differentiated drugs, and expertise in clinical development have
generated a robust, diversified, and growing pipeline of product candidates in
advanced-stage Phase 2 and Phase 3 studies. More information on Spectrum is
available at www.sppirx.com.

Forward-looking statement — This press release may contain forward-looking
statements regarding future events and the future performance of Spectrum
Pharmaceuticals that involve risks and uncertainties that could cause actual
results to differ materially. These statements are based on management's
current beliefs and expectations. These statements include but are not limited
to statements that relate to our business and its future, including certain
company milestones, Spectrum's ability to identify, acquire, develop and
commercialize a broad and diverse pipeline of late-stage clinical and
commercial products, leveraging the expertise of partners and employees around
the world to assist us in the execution of our strategy, and any statements
that relate to the intent, belief, plans or expectations of Spectrum or its
management, or that are not a statement of historical fact. Risks that could
cause actual results to differ include the possibility that our existing and
new drug candidates may not prove safe or effective, the possibility that our
existing and new applications to the FDA and other regulatory agencies may not
receive approval in a timely manner or at all, the possibility that our
existing and new drug candidates, if approved, may not be more effective,
safer or more cost efficient than competing drugs, the possibility that our
efforts to acquire or in-license and develop additional drug candidates may
fail, our lack of sustained revenue history, our limited marketing experience,
our dependence on third parties for clinical trials, manufacturing,
distribution and quality control and other risks that are described in further
detail in the Company's reports filed with the Securities and Exchange
Commission. We do not plan to update any such forward-looking statements and
expressly disclaim any duty to update the information contained in this press
release except as required by law.

SPECTRUM PHARMACEUTICALS, INC.^®, FUSILEV^®, FOLOTYN^® and ZEVALIN^®, are
registered trademarks of Spectrum Pharmaceuticals, Inc and its affiliates.
REDEFINING CANCER CARE™ and the Spectrum Pharmaceuticals logos are trademarks
owned by Spectrum Pharmaceuticals, Inc.

© 2012 Spectrum Pharmaceuticals, Inc. All Rights Reserved.

Contact:

Spectrum Pharmaceuticals
Shiv Kapoor, 702-835-6300
Vice President, Strategic Planning & Investor Relations
InvestorRelations@sppirx.com
 
Press spacebar to pause and continue. Press esc to stop.